WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010123626) CD133 POLYMORPHISMS AND EXPRESSION PREDICT CLINICAL OUTCOME IN PATIENTS WITH CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/123626    International Application No.:    PCT/US2010/025968
Publication Date: 28.10.2010 International Filing Date: 02.03.2010
IPC:
C12Q 1/68 (2006.01)
Applicants: UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; 3740 McClintock Avenue, EEB 131 Los Angeles, California 90089-2561 (US) (For All Designated States Except US).
LENZ, Heinz-Josef [US/US]; (US) (For US Only)
Inventors: LENZ, Heinz-Josef; (US)
Agent: KONSKI, Antoinette F.; FOLEY & LARDNER LLP 975 Page Mill Road Palo Alto, California 94304-1013 (US)
Priority Data:
61/172,679 24.04.2009 US
Title (EN) CD133 POLYMORPHISMS AND EXPRESSION PREDICT CLINICAL OUTCOME IN PATIENTS WITH CANCER
(FR) UTILISATION DES POLYMORPHISMES ET DE L'EXPRESSION DE CD133 POUR PRÉDIRE L'ISSUE CLINIQUE CONCERNANT DES PATIENTS CANCÉREUX
Abstract: front page image
(EN)The invention provides compositions and methods for aiding in the determination of or determining whether or not a cancer patient is likely to be responsive to a therapy comprising the administration of an anti-VEGF therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients.
(FR)La présente invention concerne des compositions et des procédés destinés à aider à déterminer si un patient cancéreux est susceptible de réagir à une thérapie comportant l'administration d'une thérapie anti-VEGF, c'est-à-dire une thérapie dirigée contre le facteur de croissance de l'endothélium vasculaire (en anglais: "Vascular Endothelial Growth Factor"). Lorsqu'on a déterminé qu'un patient est susceptible d'être traité avec succès, l'invention offre également des procédés permettant de traiter de tels patients.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)